Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Herpes zoster virus vaccine, and preparation method and applications thereof

A herpes zoster virus and vaccine technology, applied to biochemical equipment and methods, viruses, antiviral agents, etc., can solve problems that do not involve adjuvant technology

Active Publication Date: 2019-04-12
成都迈科康生物科技有限公司 +1
View PDF11 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, the aforementioned patents do not address the adjuvant technology necessary to develop an effective vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Herpes zoster virus vaccine, and preparation method and applications thereof
  • Herpes zoster virus vaccine, and preparation method and applications thereof
  • Herpes zoster virus vaccine, and preparation method and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 6

[0163] Example 6: Identification of antigenic sites of proteins expressed by herpes zoster virus gene 68

[0164] Partially overlapping 13-peptide or 20-peptide fragments covering the full amino acid sequence were synthesized for gene 68. Using these fragments, we cultured and stimulated 24 polyclonal CD4 cell lines cultured from pre-vaccination and 14 days post-vaccination polyclonal CD4 cell lines for 24 h, and then measured the concentration of interferon-γ in the supernatant. The sites that resulted in T cell responses to each protein were thus identified.

[0165] The protein expressed by gene 68 is gE protein. The results demonstrated that the major CD4 T cell loci were in the amino acid sequence 190-209 and 280-299. 75% of the vaccinated T cells responded positively to these two loci. Additional loci to which at least one third of the vaccinated T cells responded included amino acid sequences 46-65, 154-173, 199-219, 334-353 and 415-434. In addition, one-third of the...

Embodiment 7

[0169] Example 7: Isolation and Preparation of T Cell Clones of the Main T Cell Locus of the gE Protein

[0170] The two major T-cell loci of the gE protein are amino acid sequence 190-210 (RIYGVRYTETWSFLPSLTCT) and amino acid sequence 280-299 (EIEPGVLKVLRTEKQYLGVY). We cloned T cells targeting these two sites from the blood leukocytes of two vaccinated individuals and expanded them in culture.

[0171]Firstly, the quadruplets of the above two polypeptides were artificially synthesized and labeled with Allophycocyanin. The labeled quadruplets were used to react with the isolated blood leukocytes of the vaccinators. Allophycocyanin-labeled CD4-positive cells were isolated by flow cytometry. Put the isolated cells into a 96-well cell culture plate (1 cell per well) with γ-ray irradiated whole blood leukocytes (200,000 cells per well) and phytohemagglutinin (1.6 μg / well empty) To cultivate. And add human IL-2 (32 U per ml) the next day. Cultured continuously for 14 days. Fr...

Embodiment 8

[0174] Embodiment 8: the stable cell line CHO construction of the expressed gE protein

[0175] The gE protein is a glycosylated protein that needs to be expressed in eukaryotic cells to obtain a more realistic protein structure. Therefore, we constructed two Chinese Hamster Ovarian (CHO) cell lines expressing different gE protein sequences. The first cell line expresses the gE extra-enveloped sequence (amino acid sequence 31-538) without the signal peptide. The second CHO cell line expresses the fusion protein of gE protein sequence outside the envelope (amino acid sequence 31-538) and inside the envelope (amino acid sequence 560-623). The protein expressed by the second CHO cell line does not contain a transmembrane sequence (amino acid sequence 539-559) because the product of the transmembrane sequence has poor solubility and is easy to precipitate.

[0176] The construction of the cell line was carried out according to the conventional method. Primers were designed base...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to a herpes zoster virus vaccine, and a preparation method and applications thereof, and the herpes zoster virus vaccine is prepared from a varicella-zoster virus glycoprotein Eor a fragment thereof and a compound adjuvant. The compound adjuvant contains a nano-carrier and at least one molecular adjuvant that induces cellular immunity. The vaccine of the present invention iscapable of inducing a strong antibody reaction and a T cell reaction, and can achieve an optimal protective effect with little side effects.

Description

technical field [0001] The invention belongs to the technical field of vaccine preparation and relates to a herpes zoster virus vaccine. Background technique [0002] Herpes zoster is an acute infectious skin disease caused by the varicella-zoster virus. Chickenpox occurs when a child becomes infected. Due to the neurotropic nature of the virus, it can remain latent in the neurons of the dorsal root ganglia of the spinal cord for a long time after infection. When the elderly have low resistance or fatigue, infection, or cold, the virus can grow and multiply again, and move to the skin along the nerve fibers, causing intense inflammation to the affected nerves and skin. According to the CDC, nearly 1 in 3 people in the United States will develop shingles in their lifetime. There are an estimated 1 million cases of shingles each year. Special populations are at greater risk of developing shingles. This includes those who remain immunocompromised, with cancers such as leuk...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/245A61K39/39A61P31/22A61P25/02
CPCA61K39/12A61K39/39A61P25/02A61P31/22A61K2039/55544A61K2039/55577A61K2039/55555A61K2039/55561A61K2039/55566A61K2039/572A61K2039/575A61K2039/55505C12N2710/16734
Inventor 陈德祥董丽春
Owner 成都迈科康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com